iSpecimen Adds New Global Biospecimen Suppliers to Proprietary Marketplace Platform for Researchers to Leverage
July 07 2022 - 7:30AM
iSpecimen Inc. (Nasdaq: ISPC) (“iSpecimen” or the “Company”), an
online global marketplace that connects scientists in need of
biospecimens for medical research with a network of healthcare
specimen providers, announced today that it has added new global
biospecimen suppliers to its proprietary Marketplace platform for
advancing oncology and cardiovascular disease research.
The new suppliers include a cancer-focused
biobank in the United States, which contains a differentiated range
of pre- and post-treatment tissue and biofluids across multiple
cancer types. These samples provide rich data, including genetic,
treatment, follow-up and outcome information. Additionally,
iSpecimen has retained a European biobank equipped with a vast
urine and blood sample inventory from healthy participants aged 45
to 75, collected with participant health data generated from
questionnaires and disease diagnoses. This biobank contains vital
early-onset cancer and cardiovascular disease samples, as well.
“As cardiovascular disease and cancer remain the
top two leading causes of death in the U.S., respectively, these
biospecimens are among the most sought-after samples for medical
researchers,” said Christopher Ianelli, MD, Ph.D., iSpecimen
Founder and CEO. “Through adding new, distinctive biobanks to the
iSpecimen Marketplace, coupled with our recently enhanced
technology capabilities, researchers now have access to more
coveted biospecimens that can help to expedite clinical research
and bring lifesaving treatments to the market sooner for patients
in need.”
About iSpecimeniSpecimen
(Nasdaq: ISPC) offers an online marketplace for human biospecimens,
connecting scientists in commercial and non-profit organizations
with healthcare providers that have access to patients and
specimens needed for medical discovery. Proprietary, cloud-based
technology enables scientists to intuitively search for specimens
and patients across a federated partner network of hospitals, labs,
biobanks, blood centers and other healthcare organizations. For
more information, please visit www.ispecimen.com.
Forward Looking StatementsThis
press release may contain forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities Exchange Act of 1934, as amended.
Such forward-looking statements are characterized by future or
conditional verbs such as “may,” “will,” “expect,” “intend,”
“anticipate,” “believe,” “estimate” and “continue” or similar
words. You should read statements that contain these words
carefully because they discuss future expectations and plans, which
contain projections of future results of operations or financial
condition or state other forward-looking information.
Forward-looking statements are predictions, projections and
other statements about future events that are based on current
expectations and assumptions and, as a result, are subject to risks
and uncertainties. Many factors could cause actual future events to
differ materially from the forward-looking statements in this press
release, including but not limited to the risk factors contained in
the Company’s filings with the Securities and Exchange Commission,
which are available for review at www.sec.gov. Forward-looking
statements speak only as of the date they are made. New risks and
uncertainties arise over time, and it is not possible for the
Company to predict those events or how they may affect the Company.
If a change to the events and circumstances reflected in the
Company’s forward-looking statements occurs, the Company’s
business, financial condition and operating results may vary
materially from those expressed in the Company’s forward-looking
statements.
Readers are cautioned not to put undue reliance on
forward-looking statements, and the Company assumes no obligation
and do not intend to update or revise these forward-looking
statements, whether as a result of new information, future events
or otherwise.
For further information, please contact:
Media ContactsKCSA Strategic
CommunicationsRaquel Cona / Shana MarinoiSpecimen@kcsa.com
Investor ContactKCSA Strategic
CommunicationsAllison SossiSpecimen@kcsa.com
iSpecimen (NASDAQ:ISPC)
Historical Stock Chart
From Mar 2024 to Apr 2024
iSpecimen (NASDAQ:ISPC)
Historical Stock Chart
From Apr 2023 to Apr 2024